Inflammation-attenuating therapies also seem valuable in reducing the AF burden for PAF patients, as both ACE inhibitors or angiotensin receptor blocker therapy and vagus nerve stimulation effectively reduce inflammation marker levels and result in a decreased AF burden [131,142]. This evidence concerns the gene ACE and atrial fibrillation.